Please check your internet connection and try again.
```markdown
# Tamsulosin
## Overview
Tamsulosin is an alpha-1 adrenergic receptor antagonist. It selectively blocks alpha-1A and alpha-1D receptors in the prostate, bladder neck, and urethra, leading to smooth muscle relaxation and improved urine flow.
## Primary Indications
* Benign Prostatic Hyperplasia (BPH): To improve signs and symptoms of BPH.
* Ureteral Stones: To facilitate the passage of ureteral stones (off-label in some regions, but commonly used).
## Adult Dosing
* **BPH:** 0.4 mg orally once daily. If not adequately treated after 2-4 weeks, the dose may be increased to 0.8 mg orally once daily.
* **Ureteral Stones:** Typically 0.4 mg orally once daily. Dosing duration varies but is often for up to 4 weeks or until stone passage. Doses of 0.8 mg once daily have also been used.
## Pediatric Dosing
There is no established pediatric indication for tamsulosin, and it is generally not recommended for use in this population.
## Dose Adjustments
* **Renal Impairment:** No dose adjustment is generally required for mild to moderate renal impairment. Use with caution in severe renal impairment, though dose adjustment is not typically specified.
* **Hepatic Impairment:** Use with caution in patients with mild to moderate hepatic impairment as tamsulosin is metabolized by the liver. Avoid use in severe hepatic impairment.
## Contraindications
* Hypersensitivity to tamsulosin or any component of the formulation.
* History of angioedema related to tamsulosin.
* Concomitant use with other alpha-1 adrenergic receptor antagonists.
## Adverse Effects
* **Common:** Dizziness, abnormal ejaculation (e.g., retrograde ejaculation, decreased libido, anejaculation), headache, rhinitis, fatigue.
* **Serious:** Hypotension (including orthostatic hypotension), syncope, priapism, angioedema, intraoperative floppy iris syndrome (IFIS) during cataract surgery.
## Key Drug Interactions
* **Strong CYP3A4 Inhibitors (e.g., ketoconazole, ritonavir):** May increase tamsulosin exposure; use with caution or consider alternative.
* **Strong CYP2D6 Inhibitors (e.g., paroxetine):** May increase tamsulosin exposure; use with caution.
* **Other Antihypertensives (e.g., beta-blockers, ACE inhibitors, diuretics):** Increased risk of hypotension and dizziness. Monitor blood pressure.
* **Anticholinergics:** May potentially reduce the efficacy of tamsulosin.
## Monitoring
* Blood pressure, especially orthostatic vital signs, particularly upon initiation and dose increases.
* Signs and symptoms of BPH or ureteral stone passage.
* Urological symptoms.
* Patient awareness of IFIS risks if undergoing cataract surgery.
## Clinical Pearls
* Administer 0.4 mg and 0.8 mg capsules with food at the same time each day. These should not be crushed or chewed.
* Patients should be advised about the potential for dizziness and syncope, especially when standing up. Advise them to sit or lie down if they feel dizzy.
* Inform patients undergoing cataract surgery about the risk of IFIS and to inform their ophthalmologist of their tamsulosin use.
* Tamsulosin can facilitate passage of ureteral stones, particularly those in the distal ureter.
---
*This information is intended for healthcare professionals and is not a substitute for professional medical advice. Always consult the most current prescribing information and relevant clinical guidelines before making any treatment decisions.*
```
